NCT01504711View on ClinicalTrials.gov

Fosaprepitant Dimeglumine in Preventing Nausea and Vomiting in Patients With Gastrointestinal Cancer Receiving Combination Chemotherapy

NACompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

June 30, 2012

Primary Completion Date

December 29, 2016

Study Completion Date

September 3, 2020

Conditions
Gastrointestinal CancerNausea Post Chemotherapy
Interventions
DRUG

fosaprepitant dimeglumine

Given IV

Trial Locations (1)

48201

Barbara Ann Karmanos Cancer Institute, Detroit

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Philip Philip

OTHER

NCT01504711 - Fosaprepitant Dimeglumine in Preventing Nausea and Vomiting in Patients With Gastrointestinal Cancer Receiving Combination Chemotherapy | Biotech Hunter | Biotech Hunter